Latest news with #PTN
Korea Herald
23-04-2025
- Business
- Korea Herald
Top Traders Engage in Taoshi's Decentralized Trading Competition To Crowdsource Performant Investing Strategies And Earn a Share of $30M+ Rewards Pool
Leveraging Cutting Edge Blockchain and AI Technology, Top Finance-Experts Compete for Opportunity to Earn Money While Making Sophisticated Investing Opportunities Available To Everyone SAN FRANCISCO, April 23, 2025 /PRNewswire/ -- Taoshi, a leader in decentralized finance housed on the Bittensor Network, is offering top financial traders the opportunity to participate in an ongoing trading competition to develop high-performing, risk-adjusted investing strategies and join Taoshi's elite team of traders. Once traders pass the challenge period, they can compete against others for a share in a $30M+* annualized rewards pool, the largest for trading signals in the world. Taoshi seeks to attract the brightest minds in finance to solve real investing challenges by incentivizing and rewarding effective trading strategies. Taoshi is helping create blockchain's killer app: compensated, crowdsourced innovation. It is a decentralized financial technology company built on Bittensor, a permissionless decentralized economy that combines artificial intelligence (AI) and blockchain technology to create an open, peer-to-peer network for building and sharing commodities. Taoshi's Proprietary Trading Network (PTN) Bittensor Subnet 8 aggregates top-tier investing strategies from traders who successfully complete its 60-day challenge period. Taoshi's internal quant team analyzes these strategies to create a "super strategy" that adapts in real-time to market conditions. Traders who pass the 60-day challenge period immediately become eligible to earn a share of the $30m+ in annualized rewards. Additionally, individual traders or teams can optionally apply for a contract program with Taoshi, where those who pass the challenge are awarded the equivalent of $100,000 in Taoshi's Theta token, in addition to their eligibility to compete for the $30m+ in annualized rewards. In order to pass the 60-day challenge period on PTN, traders must be in the top 75th percentile of traders on the network, have at least 60 days of trading on the network and not drawdown more than 10%. Those who reach this goal then must maintain their status in the network, and then are continually rewarded in real-time every time a new block is generated, roughly every hour, incentivizing them to further improve their trading strategies. In a period of market volatility, investors benefit from collective intelligence that no single firm could match. "Hedge fund market opportunities and other advanced wealth management strategies have historically only been available to those who are already wealthy. That doesn't seem right. Our subnet pits top finance-experts in an open and transparent competition to generate high-performing, risk-adjusted trading strategies across forex, crypto and other assets," said Arrash Yasavolian, founder and CEO of Taoshi. " These expert traders are being compensated for their ability to help us build the next generation of trading strategies, leveraging AI and blockchain to crowdsource sophisticated financial intelligence, offering everyone access to investing strategies previously only available to the wealthy." Taoshi's "super strategy" will power its soon to be available wealth-building platform. With transparency, accessibility, and performance at its core, Taoshi is democratizing access to sophisticated trading tools that were once reserved for elite hedge funds and institutional investors. "This is no ordinary trading competition," added Yasavolian. "Other trading shops create competitions that are nearly impossible to beat. Taoshi's competition is designed to reward top traders, drive innovation and bring advanced trading strategies to retail and institutional investors." Traders interested in applying to the $100k Challenge or trading on PTN can find more information on Taoshi's website at About Taoshi: Founded in 2023, Taoshi, Inc. is a leading decentralized AI-based trading firm that democratizes access to advanced trading strategies and wealth-building tools through its decentralized infrastructure, blockchain transparency, and AI-driven ecosystem, which will empower individuals and institutions to invest with clarity and confidence. Taoshi's network aggregates highly performant investing strategies from finance-expert miners, creating a "super strategy" that adapts in real-time to market conditions. Taoshi's leadership team includes machine learning influencers, data scientists, and experts in developing advanced trading strategies. Together they bring years of experience to build the world's first intelligent, decentralized trading platform, benefiting retail and institutional investors. More information on Taoshi's website at
Yahoo
14-02-2025
- Business
- Yahoo
Palatin Technologies Inc (PTN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ...
Gross Product Sales: $4.3 million for the second quarter ended December 31, 2024. Net Product Revenue: $2 million for the second quarter ended December 31, 2024. Total Operating Expenses: $2.6 million, net of a $2.5 million gain on sale, for the second quarter ended December 31, 2024. Net Loss: $2.4 million for the quarter ended December 31, 2024, compared to $7.8 million for the same period in 2023. Net Cash Used in Operations: $4.8 million for the quarter ended December 31, 2024, compared to $10.5 million for the same period in 2023. Cash and Cash Equivalents: $3.4 million as of December 31, 2024. Fair Value Adjustment Loss: $8.1 million for the quarter ended December 31, 2024. Warning! GuruFocus has detected 3 Warning Signs with PTN. Release Date: February 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Palatin Technologies Inc (PTN) reported a significant decrease in net cash used in operations, from $10.5 million in the previous year to $4.8 million for the quarter ended December 31, 2024. The company achieved a reduction in net loss, reporting a net loss of $2.4 million for the quarter, compared to $7.8 million for the same period in 2023. Palatin Technologies Inc (PTN) completed a Phase 2 study on obesity treatment, with topline data expected soon, indicating progress in their research and development efforts. The company is actively engaged in discussions with potential partners for out-licensing opportunities, particularly in their ulcerative colitis and diabetic kidney disease programs. Palatin Technologies Inc (PTN) has a strategic focus on developing Melanocortin-4 receptor agonists for obesity treatment, a market projected to exceed $100 billion annually. Palatin Technologies Inc (PTN) did not record any product sales to pharmacy distributors for the second quarter ended December 31, 2024, following the sale of rights to COSAT Pharmaceuticals. The company recorded a fair value adjustment loss of $8.1 million related to warrant liabilities, impacting their financial results. Palatin Technologies Inc (PTN) reported a decrease in cash and cash equivalents, with $3.4 million as of December 31, 2024, down from $9.5 million as of June 30, 2024. The company is reliant on securing additional funding sources for future operating cash requirements, indicating potential financial constraints. Palatin Technologies Inc (PTN) faces uncertainties and risks associated with their forward-looking statements, as highlighted in their SEC filings. Q: Can you discuss the benchmarks for the upcoming obesity data and what would be considered a win for your study regarding weight loss at 8 weeks? A: Carl Spana, President and CEO, explained that the study is a signal detection study without a preconceived number. They are looking for a clear signal, such as a higher percentage of weight loss in the combined arm and key metrics like the percentage of patients achieving significant weight loss. The study aims to see if the co-administration can reverse the slowdown in weight loss seen with Tirzepatide monotherapy. They are also interested in whether Bremelanotide alone can blunt weight regain, indicating weight loss maintenance. Q: Are there additional indications you might consider beyond the broader weight loss community, such as orphan indications for MCR-4? A: Carl Spana mentioned that there is a growing opportunity for using melanocortin-4 receptor agonists in rare and orphan syndromic diseases, such as Prader Willi syndrome and Barde Bartle. Hypothalamic obesity is a significant market opportunity, and their new compounds are expected to be competitive in this space. They are likely to focus on the rare space for these indications. Q: What are the key concepts you are looking for in the obesity study? A: Carl Spana stated that they are looking for an increase in absolute weight loss on a percentage basis, without a specific magical number. The study is not optimized for a big jump but aims to get a clear signal. They are also interested in the Bremelanotide alone arm versus the placebo arm to see if it can blunt weight regain, supporting the concept of weight loss maintenance. Q: How does the investment community's viewpoint affect your study's benchmarks? A: Joseph Pantginis noted that the investment community might compare the study against benchmarks, which could drive expectations for a win from a percentage standpoint. Carl Spana acknowledged this but emphasized their approach of looking for a clear signal rather than focusing on specific benchmarks. Q: What is the significance of the upcoming data for Palatin Technologies? A: Carl Spana expressed excitement about the upcoming data and the potential impact on their strategy. The results will be crucial for their focus on Melanocortin-4 Receptor obesity assets, which they believe will play a significant role in the future of obesity treatment and weight loss management. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
